The drugmaker cites a lack of government commitments as it bets on Merck's experimental pill instead
Tamar Kahn is a Health & Science Correspondent at Business Day. She covers a range of topics including health, education, and the healthcare system, with a focus on consumer health, public health, and educational policy. Tamar's work has been featured in prominent publications such as Sowetan, Sunday Times, and Financial Mail, showcasing her expertise in health and wellness reporting.